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ABSTRACT 
Voice virilization in women may occur due to increased levels of androgens. Women with 
congenital adrenal hyperplasia (CAH) are at risk for voice virilization due to an enzyme 
deficiency that causes increased production of androgens and lack of cortisol. Female-to-male 
transsexual persons, trans men, are treated with testosterone, with virilization of the voice as a 
desired outcome. The overall aim of the project was to provide new knowledge on how 
female voice and vocal folds are affected by endogenous and exogenous androgen exposure, 
and the consequences virilization of the voice may have in a patient’s life.  
Study I: Thirty-eight women with CAH and 24 age-matched controls participated. Their 
voices were recorded and acoustically and perceptually analyzed. They answered questions 
about subjective voice problems. Endocrine data were obtained from medical journals. The 
results showed that women with CAH spoke with significantly lower mean fundamental 
frequency (F0), had darker voice quality, and rated higher on the statement “my voice is a 
problem in my daily life” than the controls. Voice virilization was associated with late 
diagnosis or problems with glucocorticoid medication, but not with severity of mutation. 
Proper treatment with glucocorticoids is important to avoid long periods of increased 
androgen levels to prevent irreversible voice virilization. 
Study II: Forty-two women with CAH and 43 age-matched controls filled out the Voice 
Handicap Index (VHI) and answered questions about voice function related to virilization. 
Endocrine data were obtained from medical journals. Women with CAH scored significantly 
higher than the controls on VHI when the results were divided into groups by voice handicap: 
none/mild, moderate, and severe. A virilized voice in women with CAH correlated with less 
voice satisfaction. Seven percent of the women with CAH had voice problems related to 
voice virilization. Voice virilization was associated with long periods of under-treatment with 
glucocorticoids and higher bone mineral density, confirming results and conclusions from 
study I. It is recommended that women with CAH who experience voice problems are 
referred for voice assessment.  
Study III: Four women with CAH and virilized voices, and 5 female and 4 male controls 
participated. A procedure for magnetic resonance imaging of the vocal folds was developed. 
The results showed that the cross-sectional area of the thyroarytenoid (TA) muscle was larger 
in women with virilized voices than in female controls, and smaller than in males. The larger 
TA area correlated with lower F0 values obtained from acoustic analysis of habitual speech 
range profiles. Thus, the anatomical explanation for voice virilization may be a larger cross-
sectional area of the TA muscle, suggesting androgen receptors in the vocal folds. These 
findings need to be confirmed in a larger study.  
Study IV: Fifty trans men participated in a longitudinal study. Voice assessments, performed 
before testosterone treatment started and regularly up to 24 months, included audio-
recordings of speech and voice range profiles and self-ratings of voice function. A significant 
lowering of mean F0 was found after 3 months, after 6 months, and up to 12 months, when 
group data were congruent with reference data for males. No correlations were found 
between levels of testosterone, EVF, Hb, SHBG or LH, and F0 values. Lower F0 values 
correlated with greater satisfaction with the voice. A quarter of the participants had received 
voice therapy for problems associated with virilization, such as vocal fatigue or unstable 
voice. Voice assessment during testosterone treatment is important to detect the potentially 
large subgroup of trans men that needs voice therapy.    
  
  
SAMMANFATTNING 
Röstvirilisering hos kvinnor kan förekomma på grund av ökade halter av androgener. 
Kvinnor med kongenital binjurehyperplasi (congenital adrenal hyperplasia, CAH) riskerar att 
få en viriliserad röst på grund av en enzymdefekt som medför ökad produktion av androgener 
och kortisolbrist. Transsexuella kvinnor-till-män, transmän, behandlas med testosteron med 
röstvirilisering som önskat resultat. Det övergripande syftet med projektet var att 
tillhandahålla ny kunskap om hur kvinnors röster och stämband påverkas av endogen och 
exogen exponering för androgener och vilka konsekvenser röstvirilisering kan ha i patienters 
liv. 
Studie I: Trettioåtta kvinnor med CAH och 24 åldersmatchade kontrollpersoner deltog. 
Deras röster spelades in och analyserades akustiskt och perceptuellt. De besvarade frågor om 
subjektiva röstproblem. Endokrinologiska data inhämtades från journaler. Resultaten visade 
att kvinnor med CAH talade med signifikant lägre grundtonsfrekvens (MF0), hade mörkare 
röstkvalitet och skattade högre värden på påståendet ”min röst utgör ett problem i mitt 
dagliga liv” jämfört med kontrollpersoner. Röstviriliseringen var associerad med sen 
diagnosticering eller problem med kortisonmedicinering, och inte med svårighetsgraden av 
CAH. En korrekt medicinering med kortison är avgörande för att undvika långa perioder av 
ökade halter av androgener med risk för irreversibel röstvirilisering. 
Studie II: Fyrtiotvå kvinnor med CAH och 43 åldersmatchade kontrollpersoner besvarade 
Rösthandikappindex (RHI) och frågor gällande röstfunktionen relaterade till röstvirilisering. 
Endokrinologiska data inhämtades från journaler. Kvinnor med CAH skattade signifikant 
högre värden på RHI när resultaten delades in i grupper: ingen/mild, måttlig och hög grad av 
rösthandikapp. En viriliserad röst hos kvinnor med CAH korrelerade med att de var mindre 
nöjda med sina röster. Sju procent av kvinnorna med CAH hade röstproblem relaterade till 
röstvirilisering. Röstvirilisering var associerad med långa perioder av underbehandling med 
kortison och högre benmineraldensitet, vilket bekräftade resultat och slutsatser från delstudie 
I. Kvinnor med CAH som har röstproblem bör remitteras för röstbedömning.  
Studie III: Fyra kvinnor med CAH och med viriliserade röster, 5 kvinnliga och 4 manliga 
kontrollpersoner deltog. En procedur för inspelning och analys med magnetisk 
resonanstomografi utvecklades för stämbandsmätningar. Resultaten visade att tvärsnittsarean 
av thyro-arytenoidmuskeln (TA) var större hos kvinnor med CAH jämfört med de kvinnliga 
kontrollpersonerna, och mindre jämfört med de manliga. En större TA-area korrelerade med 
lägre F0-värden från akustisk analys av talfonetogram. Den anatomiska förklaringen till en 
viriliserad röst kan därför vara en större tvärsnittsarea av TA-muskeln, vilket tyder på att 
androgenreceptorer finns i stämbanden. Resultaten behöver bekräftas av större studier. 
Studie IV: Femtio transmän deltog i en longitudinell studie. Röstbedömningar, innan 
testosteronbehandling inleddes och regelbundet upp till 24 månader, omfattade 
röstinspelningar av tal- och maxfonetogram samt egenskattningar av röstfunktionen. En 
signifikant sänkning av MF0 skedde efter 3 månader, efter 6 månader och efter 12 månader, 
då gruppdata var i nivå med referensvärden för manliga talare. Ingen korrelation kunde 
påvisas mellan nivåerna av testosteron, EVF, Hb, SHBG eller LH och F0-värden. Lägre F0-
värden korrelerade med att deltagaren var mer nöjd med rösten. En fjärdedel av deltagarna 
hade fått röstbehandling för röstproblem relaterade till viriliseringen, såsom rösttrötthet och 
instabilitet. Därför är röstbedömning under testosteronbehandling viktig för att upptäcka den 
relativt stora grupp transmän som behöver röstbehandling. 
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1 INTRODUCTION 
 
The voice is necessary in verbal communication and a crucial part of an individual’s identity. 
The voice contains acoustic cues, which give a listener information about the speaker’s 
gender and age, and can sound more or less feminine or masculine. The voice and the vocal 
folds can be affected by many medical conditions resulting in a changed voice pitch or 
quality, which can severely affect a person’s quality of life. One such condition is abnormal 
increase of male hormones, androgens, in women. Females can respond to increased 
androgen stimulation with changes in the larynx and a virilized voice. However, knowledge 
is insufficient about voice virilization and its consequences, which have previously been 
described only scarcely. Two patient groups are highly relevant to include in this thesis 
representing two different principles of androgen stimulation. Women with congenital 
adrenal hyperplasia (CAH) are born with an enzyme deficiency that causes lack of cortisol 
and often aldosterone and increased production of endogenous androgens and thus risk 
undesirable voice virilization. Female-to-male transsexual persons receive testosterone 
treatment with virilization of the voice as one of the desired outcomes. 
 
1.1 VIRILIZATION OF VOICE AND VOCAL FOLDS IN WOMEN  
Symptoms of voice virilization in women have been described as a lowered fundamental 
frequency (F0), loss of high frequencies, vocal instability such as involuntary shift between 
the modal and falsetto registers, hoarse or rough voice quality, creakiness, changes in timbre 
and difficulties to project the voice. These characteristics are based on results from case 
studies, small group studies, clinical experience and one prospective study (Baker, 1999; 
Berendes, 1962; Boothroyd & Lepre, 1990; Damsté, 1964, 1967; Eliakim, et al., 2011; 
Gerritsma, Brocaar, Hakkesteegt, & Birkenhager, 1994; Juniarto, et al., 2013; Martin, 1988; 
Nordenskjöld & Fex, 1984; Pattie, Murdoch, Theodoros, & Forbes, 1998; Shepperd, 1966; 
Spooner, 1977; Strauss, Liggett, & Lanese, 1985; Wollina, et al., 2007). A virilized voice 
may also be emotionally difficult as described by Tsuji et al. (2003), Baker (1999) and Van 
Gelder (1974).   
Effects of virilization on the vocal folds and the larynx have been described not to be visible 
during a laryngoscopic examination (Damsté, 1964, 1967). Three studies focused on 
investigating virilized vocal folds and larynxes in vitro. Bauer (1968) compared one woman’s 
excised virilized larynx with larynxes from vocally healthy men and women. The virilized 
vocal fold had larger dimensions of the thyroarytenoid (TA) muscle and smaller dimensions 
of connective tissue. In another study, female mice with virilized larynxes were examined. 
Hypertrophy and hyperplasia of the inner part of the TA muscle, as well as slight edema in 
the mucous membrane and the connective tissue were seen (Talaat, et al., 1987). A more 
recent study examined the vocal folds in virilized rats and it was found that the muscle fibers 
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were hypertrophic (Amer, Asker, & Mazroa, 2011). Thus, it is important to further 
investigate effects of virilization on the vocal folds in larger groups and in vivo. 
 
1.2 VOICE PRODUCTION 
Voice production requires three parts, presented below:  
 The respiratory system regulates the air pressure from the lungs during exhalation and 
the subglottal pressure generates the driving force for vocal fold vibrations.  
 The vocal folds generate the sound of the voice when they are set into vibration, thus 
being the voice source.  
 The vocal tract (VT) is the cavity in the area immediately above the vocal folds up to 
the lips, including the pharynx, oral and nasal cavities, and acts as a filter. Changes in 
the vocal tract by moving the jaw, tongue, lips, velum, and the larynx position affect 
the articulation and resonance of the voice, see Figure 1a and b. 
The vocal folds contain the cover, i.e. epithelium and the superficial layer of the lamina 
propria and the body, i.e. the intermediate and deep layers of the lamina propria and the TA 
muscle, also called the vocalis muscle (Hirano, 1974). The subglottal pressure and the 
Bernoulli effect generate the forces that produce the vocal fold vibrations (Van Den Berg & 
Zantema, 1956). The fundamental frequency (F0), the number of vocal fold vibrations per 
second (Hz), is closely related to the perceived voice pitch. Longer and thicker vocal folds, as 
in males, result in slower vibrations and a lower F0, as compared with the faster vibrations 
caused by the shorter and thinner vocal folds in females (Hirano, 1974; Titze, 1989). 
However, there is a complicated association between vocal fold mass and F0 according to 
Titze (2011), who claimed that an increase only in the vertical thickness of the vocal folds 
does not lower F0, whereas an increase of the vocal fold length or of the lateral depth of the 
vocal folds will lower F0. F0 is also regulated through stretching of the vocal folds, 
controlled mainly by activity in the cricothyroid muscle, and shortening of the vocal folds, i.e. 
changing the tonus in the TA muscle (Titze, Luschei, & Hirano, 1989). A balance between 
the cricothyroid muscle and the TA muscle activity is needed for pitch regulation and vocal 
stability. The sound pressure level (SPL) of the voice is closely related to perceived loudness 
and is regulated mainly by subglottal pressure. A higher subglottal pressure typically 
corresponds to higher SPL (Holmberg, Hillman, & Perkell, 1988). The voice quality is 
associated with both the resonances in the vocal tract and the glottal waveform (Gauffin & 
Sundberg, 1989). 
There are anatomical differences between females and males, such as females having a 
shorter vocal tract, shorter and thinner vocal folds, and a less prominent Adam’s apple (Fitch 
& Giedd, 1999). See Figure 1a and b. 
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Figure 1a and b. Images acquired in sagittal plane using MRI of a female (left) and a male (right) 
control in study III. The vocal folds (A), the Adam’s apple (B) and the vocal tract (straight lines), are 
pointed out. The VTL was 158 mm for the female and 181 mm for the male. 
 
There are differences between female and male voices as regards the acoustic parameters F0, 
SPL, the glottal waveform and the acoustic spectrum. Females typically speak with higher F0 
and lower SPL, are perceived as having more breathy voice quality and a “brighter” speech 
due to the approximately 20 percent higher formant frequencies (Coleman, 1983; Hallin, 
Fröst, Holmberg, & Södersten, 2012; Holmberg, et al., 1988; Klatt & Klatt, 1990; Pegoraro 
Krook, 1988; Sanchez, Oates, Dacakis, & Holmberg, 2014; Södersten, Hertegård, & 
Hammarberg, 1995; Södersten & Lindestad, 1990; Södersten, Lindestad, & Hammarberg, 
1991; Södersten, Ternström, & Bohman, 2005). The main acoustic variables of interest in the 
present thesis are F0 and SPL related to voice virilization in both women with CAH and 
female-to-male transsexual persons. Reference values for mean F0 (MF0) in adult vocally 
healthy Swedish females are 188 Hz and for males 116 Hz (Pegoraro Krook, 1988). 
 
1.3 TESTOSTERONE PRODUCTION AND ADMINISTRATION 
Testosterone and its derivative dihydrotestosterone are the principle androgenic virilizing 
hormones in men. These androgens are responsible for sex differentiation during the early 
fetal period, virilization at puberty, and maintenance of androgen-dependent functions in 
adult life. The potential to respond to androgen signaling remains intact throughout life in 
certain tissues, i.e. genital structures, larynx, skin, muscle, bone, the central nervous system, 
and adipose tissue. Thus, women may respond to increased androgen stimulation with 
changes in the larynx and vocal folds. Independent of age, normal serum levels of 
testosterone in adult women are 0.5-3.0 nmol/L and 10-30 nmol/L in adult men (Nieschlag, 
Behre, & Nieschlag, 2012). 
 4 
 
1.3.1 Steroid hormone synthesis 
The adrenal glands produce glucocorticoids (cortisol), mineralocorticoids (aldosterone) and 
androgens. Androgens are also derived from the ovaries, which produce 50 percent of 
testosterone in females, and the testis, which produce 90 percent of circulating testosterone in 
adult males. The steroid hormone synthesis starts with conversion of cholesterol to 
pregnenolone regulated by adrenocorticotropic hormone (ACTH)-controlled expression of 
the rate-limiting enzyme. ACTH is produced in the anterior pituitary and pregnenolone is a 
precursor for the various steroids produced by the adrenal glands. The feedback system 
regulating ACTH is mainly based on circulating levels of cortisol. Impaired production of 
cortisol leads to raised levels of ACTH and excessive secretion of adrenal androgens. To 
synthesize aldosterone the enzyme 21-hydroxylase is needed for conversion of pregnenolone, 
and 17-hydroxyprogesterone is needed for conversion of pregnenolone to produce cortisol 
(White & Speiser, 2000).   
1.3.2 Testosterone treatment in female-to-male transsexual persons 
Testosterone treatment in female-to-male transsexual persons aims to induce and maintain 
virilization and testosterone levels within the normal male range.  Monitoring of testosterone 
treatment in trans men includes assessment of testosterone levels, suppression of luteinizing 
hormone (LH), increase in erythropoesis and also sex hormone binding globulin (SHBG), a 
binding protein that mitigate the levels of free testosterone. Side effects of testosterone 
therapy may include acne and excessive stimulation of erythropoesis, while severe adverse 
reactions are rare if testosterone levels are maintained in the normal male range (Hembree, et 
al., 2009).   
 
1.4 CONGENITAL ADRENAL HYPERPLASIA IN WOMEN 
1.4.1 Clinical presentation and incidence 
Women with congenital adrenal hyperplasia (CAH), an inherited autosomal recessive 
disorder, are born with an enzyme deficiency in the adrenal glands and a defective or absent 
production of cortisol and often also of aldosterone. The lack of these hormones causes a 
feedback on the pituitary by increased ACTH stimulation, which leads to high androgen 
secretion from the adrenal glands (Merke & Bornstein, 2005; White & Speiser, 2000). For a 
description of the steroid hormone synthesis in CAH, see Figure 2. Prenatal androgen excess 
results in virilization of the external genitals in females, which can make gender decision 
difficult at birth. Treatment with glucocorticoids is vital and substitutes the cortisol 
insufficiency to prevent adrenal crisis, as well as decreasing ACTH production, which 
suppresses the increased production of adrenal androgens. Neonatal screening for CAH 
started 1986 in Sweden and the level of 17-hydroxyprogesterone is used as a disease marker; 
raised levels indicate CAH (Gidlöf, Wedell, Guthenberg, von Döbeln, & Nordenström, 
2014). In the study by Gidlöf and colleagues (2014), the efficiency of the neonatal screening 
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for CAH in Sweden was investigated and it was concluded that all cases with the most severe 
form of CAH were detected, but not all cases with milder forms of CAH. Based on data from 
the neonatal screening program in Sweden, the incidence was found to be more than one in 9 
000 live births between 1990 and 2000 (Gidlöf, et al., 2013) or one in 9 800 (Thilén, et al., 
1998), corresponding to a total of 5 girls and 5 boys receiving this diagnosis each year. CAH 
is characterized by impaired activity of one of the five enzymes in the adrenal gland. CAH 
due to 21-hydroxylase deficiency accounts for more than 90-95 percent of all patients with 
CAH (Merke & Bornstein, 2005).  
 
 
Figure 2.  Steroid hormone synthesis defect in CAH. The production of cortisol, aldosterone and 
androgens in the adrenal cortex and the enzymes involved in CAH are shown as well as the feedback 
system regulating adrenocorticotropic hormone (ACTH). A lack of the enzyme 21-hydroxylase (21-
OHD) results in insufficient cortisol production, an accumulation of 17-hydroxyprogesterone (17- 
OHP) and excessive androgen secretion. (Modified from an illustration by Anna Wedell, with 
permission). 
 
Clinically, CAH due to 21-hydroxylase deficiency is divided in three sub-groups: salt-
wasting (SW), simple virilizing (SV) and non-classic (NC) (Wedell, Thilén, Ritzen, Stengler, 
& Luthman, 1994). SW and SV are called classic CAH, and affected girls are often born with 
virilized external genitals. In SW, which is the most severe form, both cortisol and 
aldosterone deficiency occurs. SV, a milder phenotype, shows mainly cortisol deficiency and 
NC shows symptoms due to virilization later in life, i.e. early onset of puberty, hirsutism and 
infertility (Pinto, et al., 2003). A good correlation between phenotype and genotype has been 
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found (Wedell, et al., 1994). There are four genotype groups that are the most common, 
identified by to the mildest representing allele: null, I2splice, I172N and V281L, see Figure 3. 
Null is a mutation where no activity of the enzyme (21-hydroxylase) occurs and is associated 
with SW. I2splice mutation with very low activity of the enzyme is usually associated with 
SW, but sometimes with SV. Further, I172N is associated with SV and V281L with NC. 
  
 
Figure 3. The 10 genotypes that encompass 95 percent of all mutations in the population and their 
corresponding phenotypes (clinical sub-groups of CAH) and diminished enzyme activity compared to 
the normal enzyme. (Modified from an illustration by Anna Wedell, with permission). 
 
1.4.2 Voice characteristics 
Women with CAH may develop voice virilization, as described in three case reports (Fürst-
Recktenwald, Dörr, & Rosanowski, 2000; Heinemann, 1974; Tsuji, et al., 2003), see Table 1. 
Heinemann (1974) reported perceptual analysis of pitch and voice quality in 10 girls and 3 
boys with CAH, whose voices were found to have dark voice “timbre” (quality), low pitch 
and sometimes hoarse voice quality. In one case report of a 17-year-old girl with CAH, data 
on “middle F0” of 104 Hz was presented (Fürst-Recktenwald, et al., 2000). In another case 
report, a 16-year-old girl had a virilized voice with an MF0 of 160 Hz and presence of 
prominent Adam’s apple, causing discomfort to the patient (Tsuji, et al., 2003). Cricothyroid 
approximation, Isshiki’s type IV was performed to increase the pitch (Isshiki, Morita, 
Okamura, & Hiramoto, 1974). After the surgery and six sessions of voice therapy, with the 
aim of expanding F0 range and reducing strain voice quality, MF0 was raised to 220 Hz. 
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Table 1. Previous studies and voice findings in girls with CAH. 
Study n Voice  Voice assessment 
Heinemann, 1974 10 Lowering of voice pitch 
Dark voice quality 
Perceptual  
Fürst-Recktenwald et al., 
2000 
1 Deep voice 
“Middle F0” = 104 
Not described 
Tsuji et al., 2003 
 
1 Lowering of F0, MF0 = 160 
Small speaking frequency range 
Acoustic analyses 
 
1.5 FEMALE-TO-MALE TRANSSEXUAL PERSONS 
1.5.1 Clinical presentation and incidence 
Transsexualism (TS) is a medical diagnosis with the code F64.0 in the International 
Classification of Diseases (ICD-10) and the criteria “a desire to live and be accepted as a 
member of the opposite sex, usually accompanied by a sense of discomfort with, or 
inappropriateness of, one's anatomic sex, and a wish to have surgery and hormonal treatment 
to make one's body as congruent as possible with one's preferred sex” (World Health 
Organization, 2009). The diagnosis according to DSM-5 is Gender Dysphoria (American 
Psychiatric Association, 2013). In Sweden change of legal status and surgical sex-
reassignment is formally applied for at the National Board of Health and Welfare and 
regulated by Swedish law since 1972. The applicable law was amended in 2013, when the 
requirements of being sterilized and unmarried were removed. Incidence of applications for 
legal and surgical sex-reassignment in Sweden have increased significantly between 1972 
and 2010: from 0.16 to 0.42/10 000 per year for trans men and from 0.23 to 0.73/100 000 per 
year for trans women, with the sex ratio (trans men:trans women) being 1:1.66 for the time 
period (Dhejne, Öberg, Arver, & Landen, 2014). Between 2010 and 2012, in average 27 trans 
men and 31 trans women per year formally applied for change of legal status and surgical sex 
reassignment in Sweden. After the change of the law 2013 the number has increased 
considerably. 
Individuals who have been assigned female sex at birth and experience gender incongruence, 
transsexual female-to-males, will henceforth be referred to as trans men in the thesis. Trans 
men who receive the TS diagnosis experience gender incongruence, i.e. the gender identity 
contradicts the sex assigned at birth. Treatment include cross sex hormones, surgery to alter 
the chest, change of legal status, and sometimes surgical sex-reassignment. The treatment 
program is described in “Standards of care for the health of transsexual, transgender, and 
gender-nonconforming people” (Coleman, et al., 2012). Trans men receive testosterone 
treatment and today the administration contains mainly of intramuscular depot injections or 
transdermal testosterone gels. The reversible changes that occur require life-long treatment to 
maintain the effects and sex hormone levels within the normal range for males. The reversible 
changes are increased muscle mass, decreased fat mass, cessation of menses, and secondary 
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hair growth. The irreversible changes are increased clitoromegaly and deepening of the voice 
(Hembree, et al., 2009; Nieschlag, et al., 2012). 
1.5.2 Terminology 
There is a large variety in the literature as regards to the terminology for transsexualism: 
Gender dysphoria, Gender Identity Disorder, Gender incongruence and Transgender. 
Regarding individuals who are assigned female sex at birth and change their legal gender, 
there are also different terms used, such as female-to-male, FtM, and transmasculine 
(Hansbury, 2005). Trans men is a term used more lately (Wierckx, et al., 2014). The term 
transmasculine is used as an umbrella term for individuals who describe themselves as FtM 
transsexuals, trans men, or having a gender that do not fit into the societies binary 
understanding of gender (Azul, 2014). In this thesis, the term “trans men” has been chosen to 
describe individuals assigned female sex at birth and diagnosed with Transsexualism. This 
decision was based on the latest recommendation from the international organization World 
Professional Association for Transgender Health, WPATH (personal communication with 
Cecilia Dhejne). 
1.5.3 Voice characteristics 
There is a lack of information in the research literature concerning voice characteristics in 
trans men during testosterone treatment (Adler, Constansis, & Van Borsel, 2012). Previous 
studies on voice changes in trans men are presented in Table 2. Van Borsel and colleagues 
(2000) presented longitudinal data from two trans men during treatment. These trans men 
received intramuscular injections of testosterone undecanoate for 12 and 13 months. The 
largest change in F0 was noticed after four months of treatment and MF0 decreased to 155 
Hz and 132 Hz. The frequency range was also measured and found to be reduced. The 
highest F0 values were lowered, but the lowest F0 values were not lowered enough to 
maintain the range before treatment. Another case report presented longitudinal data of a 
trans man before and during 16 months of testosterone treatment with intramuscular 
injections, showing a marked decrease in F0 between the third and the fourth month 
(Damrose, 2009). MF0 of sustained /a: / for 5 seconds was analyzed and had decreased from 
228.47 Hz before treatment to 116.52 Hz. A recent controlled cross-sectional study by 
Cosyns and colleagues (2014) investigated voice characteristics and hormonal levels in 38 
trans men after testosterone treatment (9 months to 22 years). Age-matched male controls 
were included. The results showed that the median F0 and F0 variation during speaking did 
not differ significantly compared with controls. However, in 10 percent of the participants, 
the median F0 were insufficient, including participants whose F0 values were within the 
gender-ambiguous range in which the speaker’s gender is unidentifiable, and participants 
who had undergone voice therapy or pitch lowering surgery, i.e. Type 3 thyroplasty (Isshiki, 
Taira, & Tanabe, 1983). Higher levels of hematocrit and longer cysteine-adenine-guanine 
(CAG) repeats in the androgen receptor (AR) gene were reported to be associated with the 
lowest F0 values, which would suggest a dose-response relationship between androgen 
exposure and lowering of the voice (Cosyns, et al., 2014). Further, Scheidt et al. (2004) 
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investigated voice characteristics in 14 trans men who had been treated with intramuscular 
injections from 2.5 months up to 9 years. They were divided in two groups, one for those who 
had been treated for less than one year, including participants before start of treatment (n=6) 
and another group for those who had been treated for more than one year (n=8). The MF0 
values for the group treated > 12 months varied between 103 Hz to 140 Hz. A Swedish 
follow-up study by Söderpalm and colleagues (2004) reported on 22 trans women and 3 trans 
men. The initial MF0 values for the trans men were between 140 Hz and 150 Hz. One of the 
participants underwent 6 months of voice therapy and the MF0 declined from 148 Hz to 133 
Hz during treatment. After 22 months, MF0 was 113 Hz and problems with vocal fatigue 
were no longer present. 
 
Table 2. Previous studies on voice changes in trans men during testosterone treatment. 
Study n Testosterone 
duration 
 Voice Voice 
assessment 
Van Borsel et al., 2000 2 12 and 13 months  
 
MF0 = 155 and 123 Hz 
Loss of high frequencies 
Acoustic 
analyses 
 
Söderpalm et al., 2004 3 No information  
 
 
MF0 = 140 to 150 Hz 
Vocal instability 
Acoustic 
analyses 
Scheidt et al., 2004 8  > 12 months 
 
 
MF0 = 103-140 Hz 
F0 lowering 
Acoustic 
analyses 
Damrose, 2009 
 
1 16 months 
 
MF0 = 113 Hz Acoustic 
analyses 
 
Cosyns et al., 2014 38 +  
38 contr 
9 months - 22 years 
 
Median F0 = 109 Hz 
F0 lowering 
Acoustic 
analyses 
 
1.6 OTHER CONDITIONS CAUSED BY EXOGENOUS ADMINISTRATION OR 
ENDOGENOUS PRODUCTION OF ANDROGENS 
Previous studies on voice virilization due to exogenous administration or endogenous 
production of androgens are summarized in Table 3. 
Conditions for which women are treated with medications including androgens are for 
example, menopausal problems (such as osteoporosis), endometriosis, gynecological 
carcinoma, fibrocystic breast disease, sexual dysfunction, and Turner’s syndrome 
(Andersson-Wallgren & Albertsson-Wikland, 1994; Baker, 1999; Gerritsma, et al., 1994; 
Shepperd, 1966), see Table 3 for voice results. The use of anabolic steroids is also an instance 
where women receive exogenous androgens (Strauss, et al., 1985; Wollina, et al., 2007). Girls 
with Turner’s syndrome treated with hormones were followed in a longitudinal study and a 
decrease of speaking F0 was reported (Andersson-Wallgren & Albertsson-Wikland, 1994). 
Final F0 values after four years of hormone treatment were within the normal range for adult 
women in comparison to reference data, so there was no large change of F0 for this patient 
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group based on acoustic analyses. However, during the first year of treatment, voice breaks, 
rough voice quality, instability in terms of register, and difficulties singing high notes were 
noticed.  
Studies on patients’ subjective experience of voice symptoms related to voice virilization are 
scarce. Boothroyd & Lepre (1990) reported of a woman who was perceived as male on the 
phone and therefore was unable to receive employment. Further, in a case study of five 
women with virilized voices, it was mentioned in the discussion that singers complained 
more about smaller singing ranges and the inability to hit certain notes accurately (Shepperd, 
1966). Gerritsma et al. (1994) studied the effects on voice in 22 women with postmenopausal 
osteoporosis after 12 months medication with 50 mg nandrolone decanote and compared 
these subjects with 17 control subjects without medication. After one year of medication, the 
patients reported a significantly higher number of unspecified voice complaints as well as of 
changed timbre, vocal instability, voice pitch lowering and loss of high frequencies as 
compared with their controls. In addition to these self-reported results, the patients’ F0 values 
in speech were significantly lower. Perceptual analysis of their voice quality showed 
significantly higher degrees of creakiness and instability as compared with the control group 
(Gerritsma, et al., 1994). In a retrospective study, Baker (1999) described four female singers 
who developed voice changes after treatment with medicine having androgenic effects. 
Results from perceptual and acoustic analyses indicated that all four women spoke with low-
pitched voices. Reduced vocal power and endurance were also reported. All subjects had lost 
about one octave from the highest tone and gained one octave on the lowest tone as compared 
with analyses prior to medication with virilizing agents. The subjects experienced the 
virilizing effect on their voices as traumatic since it affected both their careers and social lives 
negatively (Baker, 1999).  
Eliakim et al. (2011) reported of endogenous production of androgens because of a virilizing 
adrenal tumor. Virilization of the voice and masculine appearance with hirsutism and acne in 
a 14 female athlete was described. Another case study of a patient with an ovarian Leydig cell 
tumor reported voice deepening and a prominent Adam’s apple (Juniarto, et al., 2013). 
Polycystic ovary syndrome (PCOS) affects 5 to 15 percent of women in reproductive age 
and is also characterized by hyperandrogenism (Gugatschka, et al., 2012). The voice change 
in women with PCOS has subsequently been investigated and compared with controls. In 
two studies, a lower mean F0 was detectable but no significant differences were found 
(Gugatschka, et al., 2012; Hannoun, et al., 2011). In the study by Hannoun and colleagues 
(2011), interviews with the women showed a significant difference concerning deepening 
of the voice between women with PCOS (35.3 percent of the 17 women with PCOS) and 
controls.  
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Table 3. Studies on voice virilization in women due to exogenous administration or endogenous 
production. 
Study Type of study n Voice  Voice 
assessment 
Exogenous administration of androgens 
 
Damsté, 1964 
 
 
Case reports 
 
6 
 
Low F0 
Instability 
No pitch control 
 
Not 
described 
Shepperd, 1966 
 
Case reports 5 Deep voice 
Low pitch for high and low 
notes 
Hoarseness 
Perceptual  
Damsté, 1967 
 
Case reports 6 Hoarseness 
Loss of singing voice 
Not 
described 
Strauss et al., 
1985 
Case reports of 
anabolic steroids 
10 Lower voice pitch 
Undesirable change 
Interview 
Boothroyd et al., 
1990 
Case report 1 Deep voice 18 month post 
treatment 
Perceptual 
Gerritsma et al., 
1994 
 
Prospective 
Controlled 
22  
+ 17 controls 
Voice lowering 
Hoarseness 
Changed timbre 
Loss of high F0 
Instability 
Voice 
history 
 
Acoustic 
analyses 
Andersson-
Wallgren et al., 
1994 
Case reports 4 Decreased F0 Acoustic 
analyses 
Baker, 1999 
 
Case reports 4  Low habitual voice pitch 
Loss of control of singing 
voice 
Less in vocal power 
MF0=104, 113, 99, 104 Hz 
Acoustic 
and 
perceptual 
Analyses 
 
Wollina et al., 
2007 
Case reports of 
anabolic steroids 
2 Low F0, MF0=170 
Rough and instable 
Not 
described 
 
 
Endogenous androgen production  
 
Eliakim et al., 
2011 
 
 
Case report  
Virilizing 
adrenal tumor 
 
1 
 
Voice deepening 
 
Interview 
Hannoun et al., 
2011 
 
Controlled  
Women with 
PCOS 
17 + 
21 controls 
Deepening of voice pitch 
Detectable lower MF0 
Interview 
Acoustic 
analyses 
Gugatschka et 
al., 2012 
Controlled of 
Women with 
PCSO 
24 + 
10 controls 
 
Trend toward lower MF0 Acoustic 
analyses 
Juniarto et al., 
2013 
 
Case report  
Ovarian Leydig 
cell tumor 
1 Deepening of the voice Interview 
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2 AIMS OF THE PROJECT 
 
The overall aim of the project was to provide new knowledge on a) how female voice and 
vocal folds are affected by endogenous and exogenous androgen exposure, and b) the 
consequences voice virilization may have on patients’ daily lives, with the goal to improve 
medical treatment and care for women with CAH and female-to-male transsexual persons, 
trans men.  
 
2.1 SPECIFIC AIMS  
The specific aims were to: 
 describe voice characteristics such as fundamental frequency (F0) and voice quality in 
adult women with CAH as compared with control subjects. (Study I)  
 
 examine if women with CAH have subjective voice problems. The following 
questions were adressed: Do women with CAH experience voice problems in daily 
life? Are the voice problems caused by voice virilization? (Study II) 
 
 investigate wether a virilized voice and subjective voice problems in women with 
CAH correlate with severity of the disease (genotype or phenotype) or androgen load, 
i.e. late diagnosis after first symptoms or poorly controlled medication, such as under-
treatment with glucocorticoids. (Studies I and II) 
 
 study if the area of the thyroarytenoid muscle, the length of the vocal folds and vocal 
tract length were different in women with virilized voices as compared with female 
and male controls and to correlate any such findings with F0 and voice sound pressure 
level (SPL). (Study III) 
 
 examine longitudinal changes of the voice during testosterone treatment in trans men. 
The following questions were adressed: To what extent and for how long a period of 
time does voice F0 decreases? Is voice SPL affected by testosterone treatment? Are 
trans men satisfied with the voice changes? Is voice and communication therapy 
needed? Is there a relationship between voice F0 and voice satisfaction, and between 
F0 and androgen levels? (Study IV)
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3 MATERIALS AND METHODS 
 
3.1 PARTICIPANTS 
All participants in studies I, II and III were recruited from a Swedish project studying medical 
and psychosocial health in women with CAH (Falhammar, et al., 2007a, 2007b; Frisen, et al., 
2009; Hagenfeldt, et al., 2008; Nordenskjöld, et al., 2008), including 61 women with CAH 
and 61 age-matched female control subjects. 
The participants in study IV were recruited from a total of 104 trans men who, during the 
years 2006-2014, were referred to the Department of Speech and Language Pathology, 
Karolinska University Hospital, after the diagnosis TS was confirmed by the psychiatric 
gender team at the Department of Psychiatry, Karolinska University Hospital. 
3.1.1 Women with CAH and controls: Study I 
Thirty-eight women with CAH, ranging in age between 18 and 63 years and 24 age-matched 
female controls (19 to 63 years) participated. All participants were examined at the 
Department of Speech and Language Pathology, Karolinska University Hospital in 
connection with the data collection for the larger follow-up study at the hospital. The women 
with CAH comprised 15 patients with the clinical sub-group (phenotype) SV, 10 with NC 
and 17 with SW including two different types of mutation (genotype): ten null and seven 
I2splice. All women with CAH were under good control regarding treatment with 
glucocorticoids at the time for data collection, except for two who had testosterone levels of 
5.7 and 6.8 nmol/L respectively.    
3.1.2 Women with CAH and controls: Study II 
All 61 women with CAH and 61 age-matched controls participating in the national follow-up 
project were asked to participate in study II. Forty-two women with CAH and 43 controls 
(range 25 to 71 years) accepted (response rates 69 percent and 70 percent respectively). Of 
these participants, 25 women with CAH and 18 controls were also participants in study I. The 
number of women with CAH in each of the clinical sub-groups of CAH were 20 with SW, 18 
with SV and 4 with NC, also representing four genotype groups: null (n = 10), I2splice (n = 
12), I172N (n = 16) and V281L (n = 4). All women with CAH were under good control 
regarding treatment with glucocorticoids, except for the two presented in study I. 
3.1.3 Women with CAH and controls: Study III 
The participants were four women with CAH (range 26 to 40 years) among those with the 
most virilized voices from study I (3 SW and 1 NC) and four age- and height-matched 
controls, also recruited from study I. Four vocally healthy age-matched males and one female 
control were recruited among colleagues. All women with CAH were under good control 
regarding glucocorticoid treatment. 
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3.1.4 Female-to-male transsexual persons: Study IV 
Fifty trans men (range 18 to 64 years) fulfilled the inclusion criteria, i.e. voice assessment had 
been carried out before start of testosterone treatment, and at least once more during 
treatment. The clinical routine for voice assessment was before start of testosterone treatment 
and after 3, 6, 12, 18, and 24 months. Since all trans men did not come to all visits or at the 
exact same time points, the recordings were divided into six groups with a time range in each 
group. A total of 211 recordings were included. Twenty-nine of the participants received 
intramuscular injections. Four received transdermal testosterone gel. Eight started with 
transdermal administration, which was then substituted with intramuscular injections. Nine 
participants were 18 years of age and had recently initiated testosterone treatment with 
gradual increment of intramuscular injections. 
 
3.2 VOICE RECORDINGS 
Digital audio recordings were made in a sound-treated booth at the Department of Speech and 
Language Pathology, Karolinska University Hospital following clinical routines. The voices 
were recorded using the computer programs Soundswell and Phog (Electronix Hitech, Täby, 
Sweden). An electret microphone (Sennheiser MKE-2, Sennheiser, Wennebostel, Germany) 
was mounted on a headset at a distance of 15 cm from the participant’s mouth. The SPL 
values were corrected for a mouth-to-microphone distance of 30 cm. The recordings made in 
Phog provided phonetograms: two-dimensional graphs of the voice showing the range of F0 
and SPL (Sulter, Wit, Schutte, & Miller, 1994). Details about the speech and voice tasks, 
analyses and measurements are presented in Table 4. For more specific information on the 
analyses, see sections 3.2.1, 3.2.2 and 3.2.3.  
3.2.1 Recordings and analysis of habitual voice 
The habitual speaking voice was assessed from recordings of reading a Swedish standard text 
aloud (40 seconds duration) and narration of a series of six pictures. These voice samples 
were recorded to provide a speech range profile (SRP) using Phog.  
For acoustic analyses of the SRP, the analysis tools in Phog and Swell were used for the 
following variables: mean fundamental frequency (MF0), F0-mode, lowest frequency (Min 
F0), highest frequency (Max F0), in Hz, lowest SPL (Min SPL), highest SPL (Max SPL), 
equivalent continuous sound level (Leq) in dB, and total area in semitones times decibel 
(ST*dB).  
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Table 4. Speech and voice tasks, types of analyses, and measures in study I, III and IV. 
Speech and voice tasks Analysis Measure Study 
SRP: reading Acoustic MF0 I 
  Min F0 I 
  Max F0 I 
 Perceptual Dark voice quality I 
SRP: reading and narrating Acoustic MF0 III, IV 
  F0-mode III, IV 
  Min F0 III,  
  Max F0 III,  
  Min SPL III 
  Max SPL III 
  Leq III, IV 
  Area III, IV 
VRP: sustained vowels /a: / Acoustic Min F0 III, IV 
  Max F0 III, IV 
  Min SPL III 
  Max SPL III, IV 
  Area III, IV 
Note: SRP – speech range profile, VRP – voice range profile, MF0 – mean fundamental frequency, 
Min F0 – minimum F0, Max F0 – maximum F0, SPL – sound pressure level, Leq – equivalent 
continuous sound level.  
 
3.2.2 Recordings and analysis of the physiological voice range 
Recordings of the physiological voice range were assessed to provide a voice range profile 
(VRP), following the guidelines presented by Hallin et al. (2012). The participants performed 
a VRP standing facing the computer screen changing F0 and SPL on sustained phonations 
and glissandi using the vowel /a: /. The participants were prompted by the instructor. The task 
was to use the maximal variation of F0 and SPL without using strained voice or feeling any 
vocal pain and took approximately 20-30 minutes to complete. 
For acoustic analyses of VRP the analysis tools in Phog were used for the following 
variables: lowest frequency (Min F0), highest frequency (Max F0), in Hz, lowest SPL (Min 
SPL), highest SPL  (Max SPL) in dB and total area in semitones times decibel (ST*dB). 
3.2.3 Perceptual analyses 
Perceptual analyses were performed of 69 voice recordings (38 women with CAH, 24 
controls and seven duplications) in study I. The duplicated recordings were added to the 
material for calculation of inter- and intra-judge reliability. Three trained listeners (speech 
and language pathologists) with several years of experience as voice clinicians performed the 
analyses. The Stockholm Voice Evaluation Approach, SVEA (Hammarberg, 2000) was used 
as a basis for the perceptual evaluation. Two of the authors (UN and MS) listened through the 
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material prior to the perceptual analyses, in order to choose appropriate parameters for the 
perceptual analyses as recommended by Hammarberg (2000). The following variables were 
selected for the perceptual analyses: Pitch, dark voice quality (timbre), vocal fry and 
instability. Dark voice timbre was chosen since the term was described in a previous study 
(Heinemann, 1974) and because the first author’s clinical observations when meeting women 
with CAH was that a dark voice was a characteristic feature and different from low pitch. 
Ratings were made on 100 mm visual analogue scale (VAS) where 0 mm meant “not at all” 
and 100 mm meant “high degree of”. Pitch was rated on a 200 mm VAS, where -100 
corresponded to “low pitch”, 0 to normal pitch and +100 to “high pitch”. The recordings, 
including the duplicates, were listened to in randomized order. Before the listening test 
started, a training session was conducted for “calibration” with the three judges and the first 
author. They listened in consensus to three voices (not included in the material) and discussed 
the perceptual terms so that they agreed on the meaning, especially the difference between 
dark voice timbre and low pitch. Since dark voice is not a parameter used routinely in 
perceptual analyses or in the clinic, this was an important procedure. Only the results from 
the ratings of dark voice quality are presented in study I. Information about the ratings of the 
other variables are given in an unpublished thesis report (Nygren, 2008). The patients spoke 
with significantly lower pitch, but the ratings of vocal fry and instability were very low for 
both patients and controls, thus, statistical analyses could not be performed for these 
parameters. 
 
3.3 SELF RATINGS 
In study I, a questionnaire was used concerning smoking habits, profession and ratings of 
voice function based on four statements: “my voice is hoarse”, “my voice is dark”, “my voice 
is a problem in my daily life” and “I get tired in my throat when speaking” rated on 100 mm 
VAS (0 mm = “not at all” and 100 mm = “high degree of”). 
Voice Handicap Index (VHI) is a questionnaire for self-assessment of voice problems 
including 30 statements on voice-related aspects in daily life (Jacobson, et al., 1997). The 
statements can be grouped into three subscales: a physical, a functional and an emotional 
scale. Each subscale includes scores from 0 to 40, which makes a total score of 120, where a 
higher score indicates larger voice handicap. A validated translation of VHI in Swedish (Sw-
VHI) was used in study II (Ohlsson & Dotevall, 2009). A total score > 20 indicates that an 
individual has a voice disorder according to Olsson et al. (2009). In study II, the total scores 
were divided into groups as described in Lundström et al. (2009): a score between 0 and 30 
reflected no/mild voice handicap, between 31 and 60, moderate voice handicap and between 
61 and 120, severe voice handicap. Supplementary questions with a focus on voice function 
related to voice virilization were added to Sw-VHI. Some questions were chosen from a 
rating form used for trans women, developed at La Trobe University, Australia (Dacakis, 
2000). The questions covered issues such as: amount of voice use, satisfaction with voice 
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pitch, if the voice was dark, if the voice was perceived as male on the phone, and if the 
speaker got negative reactions to their voice. 
In study IV, four statements about voice function and voice problems were rated The 
statements were: “I am perceived as male when speaking on the phone”; “I am satisfied with 
my voice”; “I am worried that my voice will reveal my native sex”; and “I get tired in my 
throat/voice or hoarse when speaking”. The rating scale changed slightly during the years of 
data collection. First, a 7-point interval scale was used where 1 indicated “never” and 7 
“always”. In the end of data collection, a 5-point scale was used where 0 indicated “never”, 1 
“almost never”, 2 “sometimes”, 3 “almost always” and 4 “always”. The statement “I am 
satisfied with my voice” which was used on the 7-point scale was formulated on the 5 point-
scale to “I am not satisfied with my voice“. In order to compare the results the answers were 
converted. Ratings from the 5-point scale were also converted to fit the 7-point scale: 0 was 
converted to 1 on the 7-point scale, 1 to 2.5, 2 to 4, 3 to 5.5 and 4 to 7.  
 
3.4 MAGNETIC RESONANCE IMAGING 
In study III magnetic resonance imaging (MRI) was performed using a 1.4 T MR scanner 
(Avanto, Siemens AG, Erlangen, Germany). Measurements of laryngeal anatomical details 
have been performed in previous studies (Kazemirad, Bakhshaee, Mongeau, & Kost, 2014; 
Sakai, Gamsu, Dillon, Lynch, & Gilbert, 1990) as well as measurements of VTL (Fitch & 
Giedd, 1999). Vocal fold length or the cross-sectional area of the TA muscle have not 
previously been measured in women with virilized voices. The method and procedure for 
using MRI measurements of the vocal folds TA muscle was developed in a series of pilot 
sessions.  
The participants were asked to breathe quietly and avoid swallowing during imaging 
acquisition (nearly 2 minutes) in order to reduce artefacts due to movement of the larynx and 
the vocal folds. Images in transverse oblique orientation were used for measurements of the 
vocal fold length (membranous part): i.e. from the vocal process of the arytenoid cartilage to 
the anterior commissure. Measurements of the cross-sectional area of the TA muscle were 
made from oblique coronal images, perpendicular to the left vocal fold. A method described 
by Roers et al. (2009) was used for measurements of the VTL using images in sagittal 
orientation. 
A routine PACS work station (Sectra-Imtec AB, Linköping, Sweden) was used for the 
measurements, which were performed by two observers. One of them was blinded to the 
material. The measurements were performed twice, with an interval of six or twelve months. 
Intra- and inter-observer reliabilities are presented in the result section 4.3. 
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3.5 INDIRECT LARYNGOSCOPY AND ANALYSES 
In study III the participants were assessed with indirect laryngoscopy with videostroboscopy 
of the vocal folds according to clinical routines at the Department of Otorhinolaryngology, 
Karolinska University Hospital.  For analyses, a protocol was developed for ratings of vocal 
folds movement, vocal fold closure pattern, presence of edema using a rating scale: no, little, 
moderate and heavy edema (while the participants phonated during inhalation), and a final 
judgment concerning if the vocal fold status was normal or not normal. Two phoniatricians 
performed the analyses blindly and independently. Analysis of the ratings showed total 
agreement between the two judges. 
 
3.6 ENDOCRINE AND MEDICAL DATA FROM MEDICAL JOURNALS 
Data on which of the three clinical sub-groups  of CAH (phenotype) each woman had was 
collected from medical journals (studies I, II and III), as well as data on type of mutation 
(genotype) (study II). In studies I, II and III, information on medical history was collected, 
i.e. age at diagnosis, period of time from first symptom to diagnosis and the period of time 
during which the women with CAH had been under-treated with glucocorticoids. Late 
diagnosis after first symptoms was defined as > 2 years of symptoms before treatment was 
initiated and under-treatment with glucocorticoids as > 12 months with high circulating 
androgen levels. Data on height, testosterone levels, body mass index, waist-hip ratio were 
also collected, as well as data on total bone mineral density (BMD), fat and lean mass 
measured with dual energy X-ray absorptiometry (DXA).  
In study IV, information on start of testosterone treatment, type of treatment regimen, doses 
and frequencies were collected. Androgen levels and related assessments from blood samples 
were collected, i.e. S-testosterone (T), S-luteinizing hormone (LH), S-sex hormone binding 
globulin (SHBG), B-hemoglobin (Hb) and B-hematocrit (EVF). 
  
3.7 STATISTICAL ANALYSES 
All statistical tests used in the four studies are presented in Table 5. Descriptive statistics 
presented as mean, median, standard deviation, range from minimum to maximum values, 
and interquartile range (P25-P75), were calculated in all four studies. The Shapiro-Wilk test 
and Levene’s test were used to check for the assumptions to use analyses of variance 
(ANOVA) and t-test. A significant effect of the within-group factor in a linear mixed model 
was further investigated through pair-wise comparisons between time points and the p-values 
were then corrected using the Bonferroni procedure. Power analysis was made for calculation 
of suitable sample size in study II.A p-value < 0.05 was considered to be statistically 
significant.  
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Table 5. Presentation of statistical tests in the four studies. 
Statistical test Study I Study II Study III Study IV 
Unpaired t-test x x   
Mann-Whitney U-test x x   
Paired t-test x   x 
Sign test x x   
Two group chi-squared test  x   
Chi-squared test  x   
Fischer’s exact test x x   
One-way ANOVA x    
Kruskal-Wallis ANOVA by Ranks x    
Linear mixed model    x 
Two-way repeated measures ANOVA x  x  
Scheffe’s post hoc test   x  
Spearman’s rank-order correlation x x  x 
Pearson’s correlation coefficients   x  
Intra class correlation ICC x  x  
 
3.8 ETHICAL CONSIDERATIONS 
The Regional Ethics board at Karolinska Institutet, Stockholm approved the studies in the 
doctoral project: Dnr 02713 (study I), Dnr 2010/1833-32 (study II), Dnr 2009/1338-32 (study 
III), and Dnr 2010/1829-31/3 (study IV). 
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4 RESULTS 
 
4.1 STUDY 1 
Voice recordings were performed, on which acoustic analyses of F0 and perceptual analyses 
of dark voice quality, were carried out in adult women with CAH and age-matched controls.  
The participants also rated voice symptoms. Endocrine data were obtained from medical 
journals. The results showed that women with CAH had significantly lower MF0, lower Min 
F0 and lower Max F0 in habitual voice as compared with age-matched control subjects. The 
result from calculations of the intrajudge reliabilities using intraclass correlation (ICC) 
regarding dark voice quality indicated very good reliability (varying between r = 0.82 to r = 
0.98) and the inter-judge reliability indicated good reliability (r = 0.71), according to 
guidelines by Landis & Kock (1977). Women with CAH were perceptually rated to have 
significantly darker voice quality than control subjects. In self-ratings, the women with CAH 
had significantly higher values for the statement “my voice is a problem in my daily life” as 
compared with controls. The 38 women with CAH were divided into two groups, one group 
with “dark voices” and one group with “normal voices”. The “dark voice“ group consisted of 
thirteen women with CAH who had lower MF0 values compared with reference values for 
vocally healthy women (Pegoraro Krook, 1988) and were perceptually rated to have dark 
voice quality. The women in the “dark voice” group had significantly higher BMI and lean 
body mass compared with their age-matched controls, which indicated long periods of high 
levels of androgens. After review of the medical history and since voice virilization was not 
correlated with severity of the disease, it was concluded that voice virilization in women with 
CAH was associated with a late diagnosis after the first symptom or with 
noncompliance/under- treatment for a longer period of time with glucocorticoids postnatally.  
  
4.2 STUDY 2 
The Sw-VHI and questions on voice function related to voice virilization were answered by 
the participants and information on endocrine data from medical journals in women with 
CAH were compared with corresponding data for age-matched controls. Women with CAH 
scored significantly higher on the Sw-VHI when the ratings were subdivided into the groups: 
no/mild, moderate and severe voice handicap. In comparison with age-matched control 
subjects, a larger proportion of patients rated moderate voice handicap, and severe voice 
handicap was only found among the women with CAH. They also rated significantly higher 
values regarding the statements “my voice is dark” and “I am perceived as male on the 
phone”. Voice problems that were related to voice virilization were found in 7 percent of the 
women with CAH. There were significant negative correlations between the ratings for “dark 
voice” and “satisfaction with voice” in women with CAH. A significant association was 
found between high ratings of dark voice and patients who had been under-treated with 
glucocorticoids for long periods and had thus had high level of androgens. 
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4.3 STUDY 3 
MRI of the vocal folds, voice recordings and acoustic analyses were assessed in women with 
CAH and virilized voices, age- and length-matched female controls and age-matched male 
controls. Measurements of vocal fold length, maximum mid-membranous cross-sectional 
area of the TA muscle, and VTL were performed by two observers using MR images. Intra- 
and interobserver reliability was calculated using ICC, and interpretation of the results was 
made according to guidelines by Landis & Kock (1977). A very good intra-observer 
reliability was found for both observers regarding all measurements (varying between r = 
0.846 and r = 0.997) and also a very good interobserver reliability (varying between r = 0.839 
and r = 0.949). Women with CAH had a significantly larger cross-sectional TA muscle area 
as compared with female controls and smaller compared with male controls. We also found a 
correlation between larger TA area and lower F0 values extracted from SRPs and VRPs. All 
F0 values of the patients extracted from the SRPs were significantly lower than for female 
controls and higher than for male controls. Analyses of VRP revealed that women with CAH 
had significantly lower Max F0 and smaller area as compared with female controls, and 
significantly higher Min F0 and smaller area as compared with male controls. SPL values did 
not differ, nor were there any differences regarding vocal fold length or VTL from the MRI 
analyses. The laryngoscopic analyses showed normal vocal fold status in all participants, 
except for two women with CAH where a small degree of edematous mucosa bilaterally was 
revealed.  
 
4.4 STUDY 4 
Voice recordings of habitual voice and physiological voice range, self-ratings of voice 
function and voice problems were assessed, and endocrine data from medical journals were 
collected in trans men before and during testosterone treatment. The F0 in trans men 
decreased significantly during the first 3 months of testosterone treatment regarding MF0 and 
F0-mode of the habitual voice, and continued to decrease significantly between 3 and 6 
months and also between 6 and 12 months. MF0 was 192 Hz before treatment, 155 Hz after 3 
months and decreased to 125 Hz after 12 months. After 12 months of treatment there was no 
further significant lowering of frequency values. The participants’ MF0 before start of 
testosterone treatment did not affect the final values of MF0. SPL values did not change 
significantly during testosterone treatment. Regarding SRP area and VRP areas, no 
significant differences were demonstrated. A significant increase was found for testosterone, 
EVF and Hb levels and a significant decrease in SHBG and LH levels. No or weak 
correlations were found between these levels and F0 values. Self-ratings regarding voice 
satisfaction significantly increased up to 6 months of treatment and lower F0 values 
correlated with greater satisfaction with the voice. Voice and communication therapy was 
needed for 24 percent of the trans men, due to problems with vocal fatigue, vocal instability, 
strained voice quality, insufficient lowering of pitch, problems to project the voice, and 
problems with the voice sounding too young. 
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5 DISCUSSION 
 
In this project, the voice and the vocal folds have been investigated in women with CAH, 
who are at risk of undesired voice virilization, and in trans men, who are treated with 
testosterone with virilization of voice as a desired outcome.  
The main findings were that: a) women with CAH had lower voice F0 compared with female 
controls on a group level, b) voice virilization was due to long periods of high levels of 
androgens, c) women with CAH may develop subjective voice problems, d) a larger area of 
the TA muscle may be the anatomical explanation for a virilized voice, e) the voice F0 in 
trans men decreased during the first three months of testosterone treatment and continued to 
decrease up to 12 months, and f) a quarter of the trans men needed voice and communication 
therapy.  
 
5.1 METHODOLOGICAL ISSUES 
5.1.1 Participants 
Study I, with a total of 38 women with CAH, study II, with 42, are the hitherto the largest 
group studies, and the only ones with age-matched controls, focusing on virilized voices in 
this small patient group. It was possible to perform statistical calculation for matched pairs 
concerning some of the variables in study I, but not all, since age-matched controls could not 
be recruited for every patient due to logistical issues. In study III, the intention was to recruit 
the seven women with the most virilized voices from study I. Three of them declined to 
participate due to lack of time or because they had already been part of other research 
projects. Despite the fact that there was a small sample size in this study, the results showed 
significant differences between cross-sectional area for women with virilized voices 
compared with both female and male controls, with no result overlap. A larger sample would 
have been desirable in order to strengthen the results. 
Study IV is the first longitudinal study of a larger group of trans men during testosterone 
treatment. The goal was to assess the voice regularly before start of testosterone treatment 
and after 3, 6, 12, 18 and 24 months of treatment. Because of the great variety of numbers of 
voice assessments and also variety regarding the time-point for each visit a linear mixed 
model was the most appropriate statistical method for analyzing the voice change from 3 to 
24 months. 
5.1.2 Acoustic analyses 
When recording VRP, it is important to ensure that a maximum voice range profile has been 
reached. Therefore, a VRP usually requires a great amount of prompting from the instructor 
and multiple attempts to reach Max and Min F0 and Max and Min SPL. Repeated trials are 
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especially important regarding phonation with soft voice to reach the lowest contour in the 
VRP. Thus, a recording of a VRP takes time; our experience is 20 to 30 minutes, in 
agreement with Hallin et al. (2012). Results from a VRP which has not been properly done 
are not reliable. Therefore, it is important to follow guidelines such as those described in 
Hallin et al. (2012) and Sanchez et al. (2014). Besides the VRP measurements, a recording of 
a VRP also gives information about voice function such as register shifts and instability, 
which are often seen in women with CAH with virilized voices and trans men during 
testosterone treatment. Some trans men can be reluctant to produce high pitch phonation, 
which may have influenced the results of Max F0 and thus of the VRP area. This is important 
to consider when recording trans men, so that they feel comfortable with the recording. 
Sometimes it may not be appropriate to force them to perform a VRP. 
5.1.3 Perceptual and subjective ratings of dark voice 
It should be noted that the term “dark voice” was used and defined differently in studies I and 
II. In the perceptual analysis in study I the term dark voice was used to describe the voice 
quality specific for a virilized voice. The listeners in study I rated both dark voice quality and 
the pitch. This was done in order to try to perceptually discriminate low voice pitch from dark 
voice quality. The women with CAH and controls in studies I and II performed subjective 
ratings of the statement “my voice is dark”, but probably did not differentiate between low 
pitch and dark voice quality. Furthermore, in study I the women with CAH were divided into 
two groups: those with “dark voices” and those with “normal voices”. The dark voice group 
was defined as women with CAH who had low MF0 compared with reference data for 
vocally healthy women (Pegoraro Krook, 1988) in combination with dark voice quality as 
perceptually rated. The group of women with CAH in study II was also divided into two 
groups: dark voice and normal voice. This division was based on their subjective ratings of 
dark voice on visual analogue scales. The ratings were analyzed using cluster analyses, 
verified through generalized cluster analysis.  
5.1.4 MRI 
Measurement of the vocal folds using MRI is difficult since the vocal folds slightly move 
during breathing with the risk of motion artefacts which may destroy the image. It was a 
challenge to train the participants to keep the vocal folds as still as possible while breathing 
and especially to avoid swallowing for 2 minutes, since the mean unstimulated saliva flow 
rate is 0.55 ml/minute (Lagerlöf & Dawes, 1985). Cotton swabs were used to absorb saliva. 
We performed several pilot MR recordings to evaluate which sequence to use to obtain the 
images with minimal artefacts, sufficient signal to noise ratio, optimal soft tissue visualization 
and reasonable imaging time. The final procedure for imaging of the cross-sectional vocal 
fold images had a fairly long imaging time of nearly 2 minutes. Due to the long imaging time, 
one data point for each subject had to be excluded because of motion artefacts making it 
unreliable for analysis. The measurements of vocal fold length, VTL and cross-sectional area 
of the TA muscle from the images were performed by two observers, who performed 
measurements of the complete material twice. The measurements showed very good intra- 
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and inter-observer reliability. One of the observers made the measurements blinded; this was 
not possible to arrange for the other observer (first author, who conducted the study). The 
possibility that this observer could be biased was considered. Since the analyses of the inter-
observer reliability showed very high ICC-values, the risk for bias was considered minimal. 
Thus, the results were presented as means of the four measurements. 
 
5.2 F0 IN WOMEN WITH CAH AND TRANS MEN 
Our results from studies I and III, that women with CAH had lower F0 compared with female 
controls, support earlier findings from case studies (Fürst-Recktenwald, et al., 2000; 
Heinemann, 1974; Tsuji, et al., 2003). Low F0 values in women with virilized voices have 
also been reported in case studies of women who were treated with medication containing 
androgens (Baker, 1999; Boothroyd & Lepre, 1990; Damsté, 1964, 1967; Shepperd, 1966) 
and in trans men during testosterone treatment (Cosyns, et al., 2014; Damrose, 2009; Scheidt, 
et al., 2004; Söderpalm, et al., 2004; Van Borsel, et al., 2000). F0 and SPL were investigated 
in study III from SRPs of habitual voice and VRPs. Results showed that women with CAH 
and virilized voices had lower F0 values compared with female controls and higher compared 
with male controls. Smaller VRP areas were found in the women with CAH and the shapes of 
the areas demonstrated register breaks between modal and falsetto registers and also loss of 
high frequencies. VRPs have not been performed previously in women with virilized voices, 
but symptoms such as instability and loss of frequencies have been reported previously 
(Baker, 1999; Damsté, 1967; Gerritsma, et al., 1994). 
Mean F0 decreased significantly in the trans men group during the first 3 months of androgen 
treatment according to the results in study IV. This is in accordance with previous 
longitudinal case studies of 3 trans men, which reported that the largest change in F0 was 
between the third and the fourth month of androgen treatment (Damrose, 2009; Van Borsel, 
et al., 2000). Our results showed that MF0 was in congruence with reference data for vocally 
healthy Swedish males after 12 months of androgen treatment (Hallin, et al., 2012). The 
results were also in accordance with those from a controlled cross-sectional study by Cosyns 
and colleagues (2014) of 38 trans men who had been treated with testosterone for a long time. 
This study did not find any significant differences between trans men and male controls 
regarding median F0 and F0 variation. In contrast to the findings reported in Cosyns et al. 
(2014), we could not find any correlation between F0 and hematocrit (a surrogate marker for 
androgen exposure). This lack of correlation may be due to a difference in dose-response 
relation between testosterone levels and erythropoiesis, and between testosterone and changes 
in F0. It is known that erythropoiesis responds to increasing levels of androgens beyond the 
normal upper reference levels for testosterone, while a series of other responses to androgens 
become saturated at a certain threshold level beyond which there is no further increase. It 
seems likely that the changes of the voice and F0 are regulated in the same way. 
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5.3 VOICE QUALITY IN WOMEN WITH CAH  
As found in study I, the women with CAH with virilized voices sounded darker in terms of 
voice quality. Since VTL was measured in study III and we found no differences between 
women with CAH and female controls, it is likely that the darker voice quality was not 
associated with lower formant frequencies, but rather with the voice source. It may be 
hypothesized that vibrations produced with virilized vocal folds, with a larger cross-sectional 
area of the TA muscle, are characterized by a longer closed phase and a shorter closing time, 
generating stronger harmonics in the higher partials of the spectrum as compared with non-
virilized vocal folds at the same pitch. Perceptual ratings of dark voice quality were assessed 
in study I. It was found to be possible to discriminate dark voice quality from ratings of voice 
pitch. Therefore, we suggest that the term dark voice is included in perceptual analyses of 
virilized voices. It is also important to investigate voice source parameters from flow 
glottograms and acoustic spectra, to define the term dark voice and to fully describe the 
characteristics of virilized voices.  
 
5.4 ANATOMICAL EXPLANATIONS FOR VOICE VIRILIZATION 
To our knowledge, measurements of the vocal folds in women with virilized voices have not 
been performed with MRI previously. In our study based on four women with CAH with 
virilized voices the main finding was that they had a larger cross-sectional TA area than 
female controls and smaller than males. A larger cross-sectional area correlated with lower 
F0. No differences were found regarding the vocal fold length or VTL between the women 
and the female controls. VTL had a tendency to be shorter in women with CAH, which is 
consistent with the fact that these women have a shorter body length (Falhammar, et al., 
2007b), which in turn is associated with shorter vocal tract (Fitch & Giedd, 1999). Our results 
from study III indicate that the underlying anatomical explanation for a virilized voice is the 
larger cross-sectional area of the TA muscle. This finding supports Bauer’s (1968), who 
investigated an excised larynx from a woman with a virilized voice and compared that with 
the larynxes of six males and six females. Our findings also support findings from two studies 
investigating changes of the larynx in female mice (Talaat, et al., 1987) and rats (Amer, et al., 
2011) after androgen treatment. An overall thickening of the vocal folds, vertically and 
horizontally, probably affects the closed phase during the vocal fold vibrations, which 
becomes longer compared with the closed phase in thin vocal folds. In thicker vocal folds, the 
adduction starts with the lower part of the vocal folds and continues with the upper part, 
causing the closed phase to become longer than in thin vocal folds. Titze (2011) described the 
complicated association between vocal fold mass and F0 and claimed that an increase only of 
the vertical thickness of the vocal folds does not lower F0, whereas an increase of the lateral 
depth of the vocal folds will lower F0. In study III, it seems likely that the larger cross-
sectional TA area was due to both an increase of vertical thickness and an increase of the 
lateral depth, since a larger TA area correlated with lower F0. In our measurements of the TA 
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area, depth and vertical thickness were not analyzed separately, which would be interesting to 
do in future studies.   
 
5.5 VOICE PROBLEMS AND VOICE TREATMENT IN WOMEN WITH CAH  
Studies I and II investigated subjectively rated voice problems in women with CAH. Tsuji et 
al. (2003) described that voice virilization in a young girl with CAH was emotionally 
difficult. Our results showed that voice problems due to voice virilization may occur in some, 
but not all, women with CAH. A virilized voice correlated with less voice satisfaction and 
seven percent had voice problems related to voice virilization. Some patients did not find a 
virilized voice, or to be perceived as male on the phone, to be a problem. Women with CAH 
seldom seek help for voice problems, which was not the case for women who developed 
virilized voices due to exogenous androgen administration (Baker, 1999; Damsté, 1964, 
1967; Shepperd, 1966). The reasons why women with CAH do not seek help are not 
investigated, but one reason may be that a virilized voice is not considered to be a problem 
compared with the severe consequences CAH may have in daily life (Falhammar, et al., 
2007a, 2007b; Frisen, et al., 2009; Hagenfeldt, et al., 2008; Nordenskjöld, et al., 2008). 
Another explanation could be that women with CAH have a much higher tendency to choose 
a male-dominant occupation and thus a virilized voice may be of somewhat smaller concern 
(Frisen, et al., 2009). One could assume that another reason is lack of knowledge about voice 
virilization among medical staff and patients, meaning that the question of voice problems 
may not be discussed.  
Based on the results from studies I and II it was suggested that the women who have voice 
problems should be referred for voice assessment and eventual voice therapy. Therapy 
programs need to be developed for women with virilized voices including exercises to 
changes the voice source characteristics. However, vocal exercises and the therapy programs 
for trans women may also be relevant with the goals to raise F0 in habitual speech and 
decrease the degree of dark voice quality (Carew, Dacakis, & Oates, 2007; Dacakis, 2000). 
Although it is not likely that the formant frequencies are lower in women with CAH, based 
on our VTL results, it may be useful to increase the vowel formant frequencies by changing 
the dimensions in the vocal tract to make the voice sound brighter. Carew and colleagues 
(2007) described techniques for trans women with the goal to increase the vowel formant 
frequencies by spreading the lips (first formant frequency) and fronting the tongue (second 
formant frequency) during speech. An important success factor is that the patient must be 
highly motivated to practice both during therapy sessions and also at home for carry-over. 
Another option for women who have problems with virilized voices and low F0 could be 
pitch-raising surgery as sometimes performed for trans women (Kanagalingam, et al., 2005; 
Isshiki, et al., 1974). Such surgery was performed in one girl with CAH who had a virilized 
voice (Tsuji, et al., 2003), and has also been described to be a method for other women with 
virilized voices (Tanabe, Haji, Honjo, & Isshiki, 1985). It is important to be aware of the 
potential side effects after surgery that have been reported in studies of trans women, such as 
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weak voice, reduced frequency range, and vocal fatigue and that voice therapy should be 
given after surgery (Hertegård, et al., 2013; Mastronikolis et al., 2013; Wagner et al., 2003). 
There is a need of long- term follow-up studies after pitch raising surgery. 
The questionnaire used in study II comprised questions with a focus on voice function related 
to voice virilization. The questions, relevant to use among women with CAH, were chosen 
from a questionnaire developed for trans women (Dacakis, 2000). This questionnaire could 
be used for women who develop a virilized voice due to either endogenous production or 
exogenous administration of androgens. A questionnaire of this kind needs to be validated for 
future use in Speech and Language clinics, as this is important for evaluation of voice therapy 
results. 
   
5.6 VOICE PROBLEMS AND VOICE TREATMENT FOR TRANS MEN 
For most trans men, it is important that the voice is congruent with their identity and with the 
physical changes of the body during testosterone treatment. A problem for some trans men 
can be that they are perceived by others to sound younger than their age. This could depend 
on vocal instability and register shifts during running speech, as can be heard in the voices of 
boys during puberty. The reason could also be associated with their short VTL, with the 
effect that the vowel formant frequencies are higher than in native male speakers.  
Most trans men do not need voice therapy, since the testosterone has a good effect causing a 
voice virilization. However, a quarter of the trans men in study IV did require voice therapy. 
Based on this result, it is suggested that trans men be referred for voice assessment during 
testosterone treatment, in order to detect any voice problems, which is supported by findings 
from previous studies (Scheidt, et al., 2004; Söderpalm, et al., 2004; Van Borsel, et al., 2000). 
Van Borsel et al. (2000) conducted a sample survey including 16 trans men. Eight of them 
had hoped for a faster and/or more distinct voice change, two liked to have a “heavier” voice, 
and one had problems due to strained voice quality. Another study by Scheidt et al. (2004) 
examined subjective voice function among other things, in 14 trans men. The results showed 
that most of them found it important to be recognized as male by their voice and 64 percent 
desired support regarding their voice problems such as reduced vocal power. Taken together, 
results from those earlier studies and from study IV, referral for voice therapy should be 
offered to this patient group.   
Therapy programs need to be developed for trans men including exercises to decrease vocal 
instability, vocal fatigue, and strained voice quality. Exercises to lower the larynx in order to 
decrease the formant frequencies may also be relevant. Interesting experiments were made by 
Coleman (1971, 1976) to investigate how listeners perceived gender in relation to F0 and 
formant frequencies. The tests were conducted with the use of an electrolarynx. In the first 
study a panel listened to recordings when female and male speakers used an electrolarynx 
with F0 of 85 Hz (Coleman, 1971). The panel identified the speaker’s gender correctly in 88 
percent of cases and was more confident rating gender for males with lower formant 
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frequencies than for females. It was concluded that resonance is an important cue for 
identification of a speaker’s gender. In the next listening test, male and female speakers used 
an electrolarynx, now with F0 at both 120 Hz and 240 Hz (Coleman, 1976). The results 
showed that the combination of male F0 and female vocal tract resonances was identified as 
male. The combination of male vocal tract resonances and female F0 values was a weak 
indicator to identify gender as female. Based on these results it was concluded that formant 
frequencies, not only F0, are important for the perception of an individual’s gender. This 
means that there is a greater chance that trans men, who have female vocal tract resonances 
and male F0 values, are identified by others as male speakers, than that trans women, with 
male vocal tract resonances and high female F0 values, are identified as female speakers. 
There is a need for a questionnaire developed for trans men, capturing voice function and 
voice problems relevant for this patient group, as well as questions about voice and identity 
(Azul, 2014; Hansbury, 2005). Questions used for trans women are not necessarily relevant 
for trans men. It seems important to develop and validate a questionnaire for trans men in the 
same way as the Transsexual Voice Questionnaire TVQMtF for trans women (Dacakis, 
Davies, Oates, Douglas, & Johnston, 2013). Such a questionnaire can be of value for 
evaluation of voice therapy outcomes. 
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6 CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
Women with CAH spoke with significantly lower MF0 and had darker voice quality than 
vocally healthy controls. They were at risk for developing a virilized voice due to late 
diagnosis or suboptimal treatment with glucocorticoids and not due to severity of the disease. 
It is important to inform both medical staff and patients that voice virilization may occur in 
women with CAH. Physicians caring for this patient group need to acknowledge the risk for 
altered voice characteristics and avoid long periods of high androgen influence, to prevent 
irreversible voice virilization. (I) 
Seven percent of the women with CAH had subjective voice problems associated with voice 
virilization and a virilized voice correlated with less voice satisfaction. The virilized voice 
was associated with long periods of under-treatment with glucocorticoids and higher bone 
mineral density, confirming the results and conclusions from study I. Based on the results, it 
is recommended that patients who experience voice problems are referred for voice 
assessment and eventually voice treatment. (II)  
A larger cross-sectional area of the thyroarythenoid muscle in the vocal folds was found in 
women with CAH and virilized voices as compared with vocally healthy female controls, 
while the area was smaller than in male controls. This result may be the anatomical 
explanation for a virilized voice in women, suggesting presence of androgen receptors in the 
vocal folds. Those findings need to be confirmed in large studies. A possible method using 
MRI for measurements of the vocal folds was presented. (III)  
In trans men, a significant lowering of MF0 was found after 3 months of testosterone 
treatment, after 6 months, and after 12 months, when group data was congruent with MF0 
reference data for Swedish adult males. Lower MF0 correlated with greater voice satisfaction. 
A quarter of the trans men had received voice therapy for problems associated with 
testosterone treatment such as vocal instability, vocal fatigue, and insufficient lowering of 
voice pitch. It is important to offer trans men voice assessment to detect the potentially large 
subgroup who need voice therapy during testosterone treatment. (IV)  
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7 FUTURE STUDIES 
 
The result of study III, that women with CAH had a significant larger cross-sectional TA 
muscle area as compared with female controls and smaller compared with male controls, 
needs to be verified in larger groups of women with virilized voices. MRI studies of the vocal 
fold muscle TA, also need to be conducted using faster gradient echo, in order to shorten the 
imaging time. Furthermore, MRI studies of the laryngeal structures would be of interest to 
perform in trans men before and after 12 months of testosterone treatment, when the male 
voice F0 has been established.  
More detailed analyses of voice quality parameters would be of interest to perform both in 
women with virilized voices and in trans men such as voice source parameters from flow 
glottograms and acoustic spectra to fully describe the characteristics of virilized voices.  
Listening tests should be performed on order to investigate how trans men are perceived by 
others regarding gender and age, as well as for more detailed perceptual analyses of voice 
quality in virilized voices. 
Validated questionnaires are needed for evaluating subjective voice problems in trans men 
and in women with virilized voices. It is also important to further investigate how trans men 
perceive their own voice in relation to their identity.  
Voice therapy programs for trans men and women with virilized voices need to be developed. 
Studies evaluating voice therapy intervention for those patient groups are highly necessary.  
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